Sermorelin Research Guide: GHRH(1-29): Mechanism & Research Overview
Sermorelin (GHRH 1-29) is the shortest fragment of growth-hormone-releasing hormone that retains full biological activity. Here is the research breakdown.
What is Sermorelin?
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of endogenous growth-hormone-releasing hormone (GHRH 1-44). The first 29 amino acids contain the full active site needed for GHRH receptor binding.
It was the first GHRH analog to receive FDA approval (as Geref) for diagnostic and pediatric growth-hormone-deficiency use, though it has since been discontinued from the commercial market in that form.
Mechanism of action
Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotropes, raises intracellular cAMP, and stimulates pulsatile GH transcription and release. Downstream, this raises hepatic IGF-1.
Compliance reminder
Sermorelin is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide identical to the first 29 residues of human GHRH(1-44). This fragment retains full GHRH receptor agonism with a simpler manufacturing profile.
How does it compare to CJC-1295 and Tesamorelin?
All three are GHRH agonists. Sermorelin (~10–20 min half-life) is the shortest; CJC-1295 without DAC (~30 min) is similar; Tesamorelin (~26–38 min, DPP-IV resistant) is the most stable; CJC-1295 with DAC (~8 days) is the longest.